Evidence map›Paper›PMID 33172431›Full record

ArticleBMC cancer2020

Functional and clinical significance of ROR1 in lung adenocarcinoma.

Giovanna Schiavone, Samantha Epistolio, Vittoria Martin, Francesca Molinari, Jessica Barizzi, Luca Mazzucchelli, Milo Frattini, Luciano Wannesson

Erratum issuedOpen access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in BMC cancer, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 12 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
12citing papers in PubMed, 1 pooled it
1.1field-weighted citation impact, top 18% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

12 citing papers in PubMed, 1 synthesis or guideline pooled it, 17 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Article
  4. Article
  5. Article
  6. Review
  7. Article
  8. Article
  9. Review
  10. Review
  11. Article
  12. The RNA interactome in the Hallmarks of Cancer.Wiley interdisciplinary reviews. RNA
    Review
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

8 authors at 2 institutions in 1 country.

Giovanna SchiavoneIstituto Oncologico della Svizzera Italiana, Via Ospedale, 6500, Bellinzona, Switzerland. giovanna.schiavone@eoc.ch.
Samantha EpistolioIstituto Cantonale di Patologia, Via in Selva 24, 6600, Locarno, Switzerland.
Vittoria MartinIstituto Cantonale di Patologia, Via in Selva 24, 6600, Locarno, Switzerland.
Francesca MolinariIstituto Cantonale di Patologia, Via in Selva 24, 6600, Locarno, Switzerland.
Jessica BarizziIstituto Cantonale di Patologia, Via in Selva 24, 6600, Locarno, Switzerland.
Luca MazzucchelliIstituto Cantonale di Patologia, Via in Selva 24, 6600, Locarno, Switzerland.
Milo FrattiniIstituto Cantonale di Patologia, Via in Selva 24, 6600, Locarno, Switzerland.
Luciano WannessonIstituto Oncologico della Svizzera Italiana, Via Ospedale, 6500, Bellinzona, Switzerland.
Istituto Cantonale di Patologia · CHUniversità della Svizzera italiana · CH

Funding

ABREOC (Advisory Board of Research of Ente Ospedaliero Cantonale) grant number 22062
6 · The paper itself

Abstract

backgroundReceptor tyrosine kinase-like orphan receptor 1 (ROR1) is normally detectable in embryonic tissues and absent in adult tissues. ROR1 was shown to inhibit apoptosis, potentiate EGFR signaling and reported to be overexpressed and associated with poor prognosis in several tumor models. This study aimed to assess the expression of ROR1 in lung adenocarcinoma (AC) patients.

methodsWe analyzed ROR1 expression by quantitative real-time PCR (qRT-PCR) in 56 histologically confirmed lung AC, stage I to IV, in addition we evaluated its association with TTF-1 (thyroid transcription factor-1) expression and the main molecular alterations involved in lung cancerogenesis.

resultsROR1 overexpression was observed in 28.6% of the entire cohort, using a cut-off of 1, or in 51.8% of the cases using the median value as threshold. Among patients without any genetic alteration, ROR1 overexpression was observed in 34.8% considering a cut-off of 1 and 52.2% considering the median value. The distribution of ROR1 was homogeneous among the different molecular categories: we found no association of ROR1 expression and the presence of gene mutations/rearrangements or the expression of TTF-1.

conclusionsROR1 overexpression could constitute a potential therapeutic target because altered in a consistent number of lung AC, especially in cases without druggable genetic alterations. ROR1 expression is independent of classical lung cancer molecular alterations and not correlated, in a Caucasian cohort, to TTF-1 expression.

Indexed as

Gene Expression Regulation, NeoplasticGene RearrangementMutationAdenocarcinoma of LungAdolescentAdultAgedAged, 80 and overBiomarkers, TumorFemaleFollow-Up StudiesHumansLung NeoplasmsMaleMiddle AgedPrognosisBiomarkers, TumorReceptor Tyrosine Kinase-like Orphan ReceptorsROR1 protein, humanEGFRNon-small cell lung cancerOverall survivalROR1Targeted therapies

Identifiers

PMID33172431
PMCPMC7653802
OpenAlexW3098335432

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.